GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alkem Laboratories Ltd (NSE:ALKEM) » Definitions » Piotroski F-Score

Alkem Laboratories (NSE:ALKEM) Piotroski F-Score : 6 (As of May. 11, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Alkem Laboratories Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alkem Laboratories has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Alkem Laboratories's Piotroski F-Score or its related term are showing as below:

NSE:ALKEM' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 7
Current: 6

During the past 13 years, the highest Piotroski F-Score of Alkem Laboratories was 7. The lowest was 2. And the median was 5.


Alkem Laboratories Piotroski F-Score Historical Data

The historical data trend for Alkem Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alkem Laboratories Piotroski F-Score Chart

Alkem Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 6.00 6.00 6.00

Alkem Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 6.00 - - -

Competitive Comparison of Alkem Laboratories's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Alkem Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alkem Laboratories's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alkem Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Alkem Laboratories's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Net Income was ₹9,842 Mil.
Cash Flow from Operations was ₹16,825 Mil.
Revenue was ₹114,404 Mil.
Gross Profit was ₹64,580 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was (140691.9 + 137566.3) / 2 = ₹139129.1 Mil.
Total Assets at the begining of this year (Mar22) was ₹140,692 Mil.
Long-Term Debt & Capital Lease Obligation was ₹703 Mil.
Total Current Assets was ₹87,297 Mil.
Total Current Liabilities was ₹37,072 Mil.
Net Income was ₹16,456 Mil.

Revenue was ₹105,120 Mil.
Gross Profit was ₹62,287 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was (115192.6 + 140691.9) / 2 = ₹127942.25 Mil.
Total Assets at the begining of last year (Mar21) was ₹115,193 Mil.
Long-Term Debt & Capital Lease Obligation was ₹759 Mil.
Total Current Assets was ₹84,354 Mil.
Total Current Liabilities was ₹48,053 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alkem Laboratories's current Net Income (TTM) was 9,842. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Alkem Laboratories's current Cash Flow from Operations (TTM) was 16,825. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar22)
=9841.7/140691.9
=0.06995214

ROA (Last Year)=Net Income/Total Assets (Mar21)
=16456.2/115192.6
=0.14285813

Alkem Laboratories's return on assets of this year was 0.06995214. Alkem Laboratories's return on assets of last year was 0.14285813. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Alkem Laboratories's current Net Income (TTM) was 9,842. Alkem Laboratories's current Cash Flow from Operations (TTM) was 16,825. ==> 16,825 > 9,842 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=703.3/139129.1
=0.00505502

Gearing (Last Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=758.5/127942.25
=0.00592846

Alkem Laboratories's gearing of this year was 0.00505502. Alkem Laboratories's gearing of last year was 0.00592846. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=87296.8/37071.5
=2.35482244

Current Ratio (Last Year: Mar22)=Total Current Assets/Total Current Liabilities
=84354.3/48053.4
=1.75542834

Alkem Laboratories's current ratio of this year was 2.35482244. Alkem Laboratories's current ratio of last year was 1.75542834. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Alkem Laboratories's number of shares in issue this year was 119.565. Alkem Laboratories's number of shares in issue last year was 119.565. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=64580.3/114403.5
=0.56449584

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=62287.4/105120.3
=0.59253446

Alkem Laboratories's gross margin of this year was 0.56449584. Alkem Laboratories's gross margin of last year was 0.59253446. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar22)
=114403.5/140691.9
=0.81314916

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar21)
=105120.3/115192.6
=0.91256122

Alkem Laboratories's asset turnover of this year was 0.81314916. Alkem Laboratories's asset turnover of last year was 0.91256122. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Alkem Laboratories has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Alkem Laboratories  (NSE:ALKEM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Alkem Laboratories Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Alkem Laboratories's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Alkem Laboratories (NSE:ALKEM) Business Description

Traded in Other Exchanges
Address
Senapati Bapat Marg, Alkem House, Devashish Building, Lower Parel, Mumbai, MH, IND, 400 013
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.

Alkem Laboratories (NSE:ALKEM) Headlines

No Headlines